Home | Sitemap | Search | Contact A- A A+
   
 
    Public Member Support us  
 

IBCSG 11-93 

Ovarian ablation followed by tamoxifen with or without 4 cycles of AC as adjuvant therapy for premenopausal women, node positive, hormone receptor positive breast cancer patients who are suitable for endocrine therapy alone.

DESIGN

Design Trial 11-93

Results & Publications


Publications

Study Chairs
Prof. Beat Thürlimann - St. Gallen, Switzerland
Prof. Monica Castiglione - Bern, Switzerland

Statistician
Karen Price

Trial Coordinator
Holly Shaw

Data Managers
Joie Celano, Dawn Weinbaum

IBCSG Data Management Center/FSTRF
4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 836 6097
Email: ibcsg10-15@fstrf.org

Date of Activation
May 1, 1993

Date of Closure
November 1, 1998

Targeted Accrual
400 patients

Final Accrual
174 patients


Results Publications Results & Publications
Other Pathology


News

16.01.2012:
A few impressions from our audits

28.11.2011:
Latest SOLE flash

04.11.2011:
BIG 1-98 12-year update published

All News

 
  Print